• Verastem scheduled an investor call for June 23, 2026, to update the VS-7375 oral KRAS G12D inhibitor TARGET-D program.
• New preliminary Phase 1/2 TARGET-D 101 findings will be presented, covering safety, tolerability, pharmacokinetics, and patient case studies.
• Readout spans dose-escalation and expansion cohorts in KRAS G12D-mutated advanced solid tumors, including pancreatic cancer, colorectal cancer, and NSCLC.
• Program has broadened into three Phase 2, registration-directed trials targeting pancreatic ductal carcinoma, NSCLC, and metastatic colorectal cancer.
• FDA granted Fast Track Designation for VS-7375 in pancreatic cancer in July 2025, followed by NSCLC in June 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Verastem Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202606151601BIZWIRE_USPR_____20260615_BW846661) on June 15, 2026, and is solely responsible for the information contained therein.